SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

TELA

TELA Bio, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3d 11h ago SEC0001193125-26-460552
Passive stake amendment
Actionable Insight • Neutral

Monitor for any future conversion to a 13D filing or increase in stake that could signal activist intent. The passive certification limits near-term control-related actions.

DirectionNeutral
Confidencemedium
Horizonimmediate
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

North Run Capital, LP filed an amended Schedule 13G disclosing beneficial ownership of 3,528,296 shares of TELA Bio common stock, representing 7.8% of shares outstanding as of September 30, 2026. This is an amendment to a prior filing; no prior stake data for North Run is available in the provided documents to determine direction of change. The filing is a routine passive stake update with no material new information.

Key Financial Metrics

Stake
7.8%
Investor
North Run Capital, LP
Investor Type
hedge fund

Key Facts

  • North Run Capital, LP and related entities beneficially own 3,528,296 shares of TELA Bio common stock.
  • Stake represents 7.8% of outstanding shares as of September 30, 2026.
  • Shares held by North Run - Due North Partners, LP, a pooled investment vehicle managed by North Run Capital.
  • Filing certifies passive intent under Rule 13d-1(c); securities not held to change or influence control.
  • No prior North Run 13G filings for TELA Bio are present in the provided cross-filing context to compare stake changes.

Financial Impact

7.8% passive stake in TELA Bio, valued at approximately $3.35M based on $43M market cap.

ownership

Risk Factors

  • No prior stake data available to assess direction of change; this could be a new position or an amendment to an existing one.
  • Passive filing status could change if North Run later engages with management or seeks board representation.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001193125-26-460552
Document: 0001193125-26-460552-index.html0001193125-26-460552
Document: 0001193125-26-460552.txt0001193125-26-460552

Track record

20 reports on TELA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +18.61% at T+5 after the Aug 10, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.7610 Now $0.7620 +0.13% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8200 Now $0.7620 −7.07% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $0.8201 Now $0.7620 −7.08% settles Nov 23
  4. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  5. Nov 10, 20266d ago Press Release Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  6. Oct 27, 202620d ago Press Release Neutral 2/10 Entry $0.9760 to $0.8378 Now $0.7620 −21.93% ▼ −14.16% −13.45% vs SPY
  7. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.07 to $1.10 Now $0.7620 −28.79% ▲ +2.34% +3.32% vs SPY
  8. Oct 5, 20266w ago 8-K Bullish 5/10 Entry $1.14 to $1.08 Now $0.7620 −33.16% ▼ −5.26% −5.69% vs SPY
  9. Aug 31, 202611w ago 8-K Mixed 6/10 Entry $0.7380 to $0.8301 Now $0.7620 +3.25% ▲ +12.48% +12.62% vs SPY
  10. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $0.7900 to $0.6430 Now $0.7620 +3.54% ▲ +18.61% +18.20% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 5h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026